Journal Mobile Options
Table of Contents
Vol. 5, No. 3-4, 2008
Issue release date: March 2008
Neurodegenerative Dis 2008;5:140–142

Intraneuronal β-Amyloid Is a Major Risk Factor – Novel Evidence from the APP/PS1KI Mouse Model

Bayer T.A. · Breyhan H. · Duan K. · Rettig J. · Wirths O.
aDepartment of Psychiatry, Division of Molecular Psychiatry, University of Goettingen, Goettingen, and bInstitute of Physiology, Saarland University, Homburg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Accumulating evidence points to an important role of intraneuronal β-amyloid (Aβ) in the development of Alzheimer’s disease (AD), with its typical clinical symptoms like memory impairment and changes in personality. We have previously reported on the Aβ precursor protein and presenilin-1 knock-out (APP/PS1KI) mouse model with abundant intraneuronal Aβ42 accumulation and a 50% loss of CA1 neurons at 10 months of age. In addition, we observed reduced short- and long-term synaptic plasticity, hippocampal neuron loss, and reduced performance in a working memory task. These observations support a pivotal role of intraneuronal Aβ accumulation as a principal pathological trigger in AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991;12:383–388.
  2. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
  3. Glenner GG, Wong CW: Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885–890.
  4. Wirths O, Multhaup G, Bayer TA: A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide – The first step of a fatal cascade. J Neurochem 2004;91:513–520.
  5. Hsia AY, Masliah E, McConlogue L, et al: Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci USA 1999;96:3228–3233.
  6. Moechars D, Dewachter I, Lorent K, et al: Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 1999;274:6483–6492.
  7. Holcomb L, Gordon MN, McGowan E, et al: Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 1998;4:97–100.
  8. Puolivali J, Wang J, Heikkinen T, et al: Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice. Neurobiol Dis 2002;9:339–347.
  9. Billings LM, Oddo S, Green KN, McGaugh JL, Laferla FM: Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 2005;45:675–688.
  10. Oakley H, Cole SL, Logan S, et al: Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006;26:10129–10140.
  11. Gimenez-Llort L, Blazquez G, Canete T, et al: Modeling behavioral and neuronal symptoms of Alzheimer’s disease in mice: a role for intraneuronal amyloid. Neurosci Biobehav Rev 2007;31:125–147.
  12. Wirths O, Multhaup G, Czech C, et al: Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci Lett 2001;306:116–120.
  13. Wirths O, Multhaup G, Czech C, et al: Intraneuronal APP/Abeta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice. Brain Pathol 2002;12:275–286.
  14. Blanchard V, Moussaoui S, Czech C, et al: Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Exp Neurol 2003;184:247–263.
  15. Shie FS, LeBoeur RC, Jin LW: Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice. Neuroreport 2003;14:123–129.
  16. Schmitz C, Rutten BP, Pielen A, et al: Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer’s disease. Am J Pathol 2004;164:1495–1502.
  17. Casas C, Sergeant N, Itier JM, et al: Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 2004;165:1289–1300.
  18. Wirths O, Weis J, Kayed R, Saido TC, Bayer TA: Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol Aging 2007;28:1689–1699.
  19. Wirths O, Breyhan H, Schafer S, Roth C, Bayer TA: Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer’s disease. Neurobiol Aging DOI: 10.1016/j.neurobiolaging.2006. 12.004.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00